Category: Corporate NewsBy Rameda AdminAugust 7, 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceNextNext post:Earning Release One Pager 2Q24Related PostsRameda One-Pager 1Q25May 13, 2025Earnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024Earning Release One Pager 2Q24August 13, 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024
